Leitlinie zur Diagnostik und Therapie der tiefen Bein- und Beckenvenenthrombose^[*]

 

^* Diese Leitlinie wurde auf der gemeinsamen Vorstands- und wissenschaftlichen Beiratssitzung der Deutschen Gesellschaft für Phlebologie (DGP) am 24. September 2003 verabschiedet. Diese Leitlinie berücksichtigt den aktuellen Stand der Literatur, aber nicht die in jedem Fall unterschiedlichen Zulassungsbestimmungen für die verschiedenen Pharmaka.

• Literatur

• 1 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; i: 1309-12.
• 2 Brandjes DPM. et al. Randomised trial of effects of compression stockings in patients with symptomatic proximal venous thrombosis. Lancet 1997; 349: 759. (P I)
• 3 Prandoni P. et al. Benefit of below-knee elastic compression stockings for prevention of the post-thrombotic syndrome in patients with proximal-vein thrombosis. A prospective controlled randomized study. Pathophysiol Haemost Thromb. 2002 32 (suppl 2). (P I)
• 4 Wells PS. et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350: 1795. (D I)
• 5 Bigaroni A. et al. Is clinical probability assessment of deep vein thrombosis by a score really standarized?. Thromb Haemost 2000; 83: 788. (D I)
• 6 Arcelus JJ. et al. The role of risk assessment and rapid whole-blood D-dimer testing for the diagnosis of deep vein thrombosis in symptomatic patients. JP 2002; 2: 57. (D I)
• 7 Chagnon I. et al. Comparison of two clinical prediction rules and implicit assessment among patients with suspected pulomnary embolism. Am J Med 2002; 113: 269. (D I)
• 8 Schellong SM. et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 2003; 89: 228. (D I)
• 9 Elias A. et al. A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limb. Thromb Haemost 2003; 89: 221. (D I)
• 10 Gottlieb RH. et al. Randomized prospective study comparing routine versus selective use of sonography of the complete calf in patients with suspected deep venous thrombosis. AJR 2003; 180: 241. (D I)
• 11 Bounameaux H. et al. Rapid diagnosis of deep vein thrombosis in symptomatic patients: a comparison between four different diagnostic strategies. Thromb Haemost 1999; 82: 1360. (D I)
• 12 Van der Graaf F. et al. Exclusion of deep venous thrombosis with D-dimer testing. Comparison of 13 D-dimer methods in 99 outpatients suspected of deep venous thrombosis using venography as reference standard. Thromb Haemost 2000; 83: 191. (D Ia)
• 13 Schutgens RE. et al. Combination of normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation 2003; 107: 593. (D II)
• 14 Kelly J. et al. Role of D-dimers in diagnosis of venous thromboembolism. Lancet 2002; 359: 456. (D I)
• 15 Palareti G. et al. D-dimer test performed after oral anficoagulation is stopped has a high negative predictive value for recurrence of thrombosis in patients with thrombophilic alterations and previous venous thromboembolism. Pathophysiol Haemost Thromb. 2002 32 (suppl 2). (P II)
• 16 Wells PS. et al. Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and non invasive diagnostic tests. Semin Thromb Hemost 2000; 26: 643. (D I)
• 17 Comerota AJ. et al. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg 1993; 36: 359. (T Ib)
• 18 Meyerovitz MF. et al. Short-term response to thrombolytic therapy in deep venous thrombosis: predictive value of venographic appearance. Radiology 1992; 184: 345. (T Ia)
• 19 Largiadèr J. et al. Therapeutic concept for acute leg and pelvic venous thrombosis. Acta Chir Belg 2002; 102: 356. (T IIb)
• 20 O’Meara JJ. et al. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330: 1864. (T IIa)
• 21 The Columbus Investigators.. Low-molecularweight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657. (T Ia)
• 22 Simmoneau G. et al. A comparison of lowmolecular- weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663. (T IIa)
• 23 Harenberg J. et al. Therapie der Beinvenenthrombose mit niedermolekularen Heparinen. Deutsches Ärzteblatt 1997; 94: 2257. (T Ia)
• 24 Diuguid DL. Oral anticoagulant therapy for venous thromboembolism. N Engl J Med 1997; 336: 433. (T Ib)
• 25 Raschke RA. et al. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 1993; 119: 874. (T Ia)
• 26 Arzneimittelkommission der deutschen Ärzteschaft, Bekanntgabe zur Heparin-induzierten Thrombozytopenie; Deutsches Ärzteblatt 96, 6 (12. Februar 1999).
• 27 Gruel Y. et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121: 786-92.
• 28 Kovacs MJ. et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomised, double-blind, controlled trial. Ann Intern Med 2003; 138: 714-9.
• 29 Breddin HK. et al. Effects of a low-molecularweight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626. (T Ib)
• 30 Pinede L. et al. Comparion of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453. (T Ib)
• 31 Hyers TM. et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S. (T Ia)
• 32 Prandoni P. et al. Residual venous thrombosis as a predictive factor for recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955. (P I)
• 33 Cushman M. et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003; 101: 1243. (T Ib)
• 34 Ridker PM. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34. (T Ia)
• 35 Kearon C. et al. Comparison of low-intenity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
• 36 Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Expert Rev Anticancer Ther 2002; 2: 227.
• 37 Lee AYY. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
• 38 Partsch H. et al. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000; 32: 861.
• 39 Blättler W. et al. Methods of and compliance with leg compression for the treatment of symptoms of deep vein thrombosis. Phlebologie 2001; 30: 145.
• 40 Lofferer O. et al. Die ambulante Therapie der tiefen Beinvenenthrombosen mit Kompressionsverbänden (Möglichkeiten und Grenzen). In: Ehringer H. (ed). Akute tiefe Becken- und Beinvenenthrombose. Bern: Hans Huber; 1977: 184. (T IIa)
• 41 Blättler W. Ambulatory care for ambulant patients with deep vein thrombosis. J Mal Vasc 1991; 16: 137. (T IIb)
• 42 Levine M. et al. A comparison of low-molecular- weight heparin administered primary at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677. (T Ib)
• 43 Koopman MMW. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 677. (T Ib)
• 44 Baldrige ED. et al. Clinical significance of freefloating venous thrombi. J Vasc Surg 1990; 11: 62. (P II)
• 45 Pacouret G. et al. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis. Arch Intern Med 157 1997; 305-8. (P I)
• 46 Bossuyt PM. Out of hospital treatment of venous thrombosis: Socioeconomic aspects and patient’s quality of life. Hemostasis 1998; 28: 100. (T IIb)
• 47 Frank D. et al. Vergleich von ambulanter und stationärer Behandlung der akuten tiefen Beinvenenthrombose: subjektive und ökonomosche Aspekte. Schweiz Med Wschr 1998; 128: 1328. (T Ib)
• 48 Offermann M. et al. Die ambulante Therapie der akuten tiefen Beinvenenthrombose. Dtsch Med Wschr 2001; 126: 1164. (T IIb)
• 49 Gerlach H. et al. Kontrollierte Einführung der ambulanten Behandlung der akuten tiefen Beinvenenthrombose – Machbarkeitsstudie an 827 Patienten. Phlebologie 2002; 31: 77. (T IIb)
• 50 Mostbeck A. et al. Lungenembolie bei Bein- Beckenvenenthrombose: Ergebnisse einer prospektiven Studie. Diagnostik, Häufigkeit, nuklearmedizinisches und klinisches Erscheinungsbild. Wien Klin Wschr 1980; 92: 464-71.
• 51 Huisman MV. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95: 498. (D II)
• 52 Partsch H. et al. Frequency of pulmonary embolism in ambulant patients with pelvic vein thrombosis: A prospective study. J Vasc Surg 1992; 16: 715. (T IIb)
• 53 Decousus H. et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1988; 338: 409.
• 54 Mills TD. et al. The use of vena cava filters. Hosp Med 2001; 62: 327. (T IIb)
• 55 Pradoni P. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128. (T Ib)
• 56 Nordström M. et al. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891. (P I)
• 57 Netzer P. et al. Wert des Abdomenultraschalls bei tiefer Venenthrombose. Schweiz Med Wschr 1996; 126: 58S.
• 58 Rosendaal FR. et al. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86: 112. (P II)
• 59 Scarabin PY. et al. on behalf of the Estrogen and ThromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
• 60 Baglin T. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-6.
• 61 Hansson PO. et al. Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med 2000; 160: 769-74.
• 62 Kearon C. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 63 Rey E. et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901. (P II)
• 64 Quéré I. et al. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 2002; 359: 747. (D II)